Rituximab therapy for severe refractory chronic Henoch-Schönlein purpura.
To report on the efficacy of rituximab (RTX) therapy in standard treatment-refractory, chronic Henoch-Schönlein purpura, a retrospective chart review of 3 pediatric patients treated with RTX for severe refractory chronic Henoch-Schönlein purpura was performed. All 3 patients responded to 1 or 2 courses of RTX without serious adverse events.
Donnithorne
Katherine J
KJ
University of Alabama at Birmingham School of Medicine, Birmingham, AL, USA.
Atkinson
T Prescott
TP
Hinze
Claas H
CH
Nogueira
Janaina B
JB
Saeed
Shehzad A
SA
Askenazi
David J
DJ
Beukelman
Timothy
T
Cron
Randy Q
RQ
D000293:Adolescent; D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D002648:Child; D004351:Drug Resistance; D005260:Female; D006801:Humans; D011695:IgA Vasculitis / Q000188:drug therapy*; D007155:Immunologic Factors / Q000627:therapeutic use*; D008297:Male; D012189:Retrospective Studies; D000069283:Rituximab; D012720:Severity of Illness Index
D000305:Adrenal Cortex Hormones; D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D007155:Immunologic Factors; D000069283:Rituximab